Visit-to-Visit Variability of BP and CKD Outcomes
Open Access
- 1 March 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 11 (3), 471-480
- https://doi.org/10.2215/cjn.04660415
Abstract
Background and objectives Increased visit-to-visit variability of BP is associated with cardiovascular disease risk. We examined the association of visit-to-visit variability of BP with renal outcomes among 21,245 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Design, setting, participants, & measurements We measured mean BP and visit-to-visit variability of BP, defined as SD, across five to seven visits occurring 6–28 months after participants were randomized to chlorthalidone, amlodipine, or lisinopril. The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization. We repeated the analyses using average real variability and peak value of systolic BP and for visit-to-visit variability of diastolic BP. Results Over a mean follow-up of 3.5 years, 297 outcomes occurred. After multivariable adjustment, including baseline eGFR and mean systolic BP, the hazard ratios for the composite end point were 1.29 (95% confidence interval [95% CI], 0.75 to 2.22), 1.76 (95% CI, 1.06 to 2.91), 1.46 (95% CI, 0.88 to 2.45), and 2.05 (95% CI, 1.25 to 3.36) for the second through fifth (SD of systolic BP =6.63–8.82, 8.83–11.14, 11.15–14.56, and >14.56 mmHg, respectively) versus the first (SD of systolic BP P trend =0.004). The association was similar when ESRD and a 50% decline in eGFR were analyzed separately, for other measures of visit-to-visit variability of systolic BP, and for visit-to-visit variability of diastolic BP. Conclusions Higher visit-to-visit variability of BP is associated with higher risk of renal outcomes independent of mean BP.This publication has 35 references indexed in Scilit:
- Relationships between metrics of visit-to-visit variability of blood pressureJournal of Human Hypertension, 2013
- Impact of visit-to-visit variability of blood pressure on deterioration of renal function in patients with non-diabetic chronic kidney diseaseHypertension Research, 2012
- Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African AmericansHypertension Research, 2011
- The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General PopulationHypertension, 2011
- Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertensionThe Lancet, 2010
- Awake Blood Pressure Variability, Inflammatory Markers and Target Organ Damage in Newly Diagnosed HypertensionHypertension Research, 2008
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2000
- Blood pressure, stroke, and coronary heart disease *1Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasThe Lancet, 1990
- A General Method of Compliance Assessment Using Centralized Pharmacy RecordsMedical Care, 1988